Dianthus Therapeutics Inc... (DNTH)
Dianthus Therapeutics Inc. (DNTH) Stock Price, Analysis & Data
No data available
| Bid | 82.42 |
| Market Cap | 6.34B |
| Revenue (ttm) | 1.9M |
| Net Income (ttm) | -192.25M |
| Beta | 0.08 |
| EPS (ttm) | -4.25 |
| PE Ratio (ttm) | n/a |
| Forward PE | -23.89 |
| P/B (ttm) | 5.30 |
| P/S (ttm) | 3253.56 |
| Earnings Date | Nov 5, 2026 |
| Ask | 146.7 |
| Volume | 564,807 |
| Avg. Volume (20D) | 1,069,050 |
| Open | 115.32 |
| Previous Close | 115.96 |
| Day's Range | 113.29 - 116.44 |
| 52-Week Range | 20.69 - 116.47 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce...
Financial Performance
In 2025, Dianthus Therapeutics's revenue was 2.04M, a decrease of -67.35% compared to the previous year's 6.24M. Earnings were -162.34M, an increase of 91.05%.
Financial StatementsEarnings Surprise
Analysts project revenue of ... Upgrade
2 months ago · Simply Wall St.
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks LingerDianthus Therapeutics reported a 75% response rate in a late-stage trial of claseprubart in CIDP. The update comes shortly after Sanofi discontinued a similar CIDP trial, leaving fewer competitors in ...
